David Moatazedi has served as the Evolus president, CEO and member of the board of directors since May 2018. During this time, the company launched botulinum toxin Nuceiva, and is due to release dermal filler range Estyme to the UK market in 2025.
As of 2024, the brand has been identified as the fastest growing company in the medical aesthetics sector for the third consecutive year. Moatazedi attributes this success to the company’s focus on having a specific target market: millennials.
He explains that the origination of Evolus centres around the concept of ‘evolve with us.’ From the outset, the product was designed with a focus on the millennial generation. “This is because this demographic views aesthetics differently than their parents, seeing it as a beauty product rather than a clinical medical treatment.
By targeting this younger audience, we saw a significant opportunity to differentiate ourselves from traditional medical companies,” he notes. Here, he tells the Aesthetics Journal how the company…
